Decreased level of soluble receptor activator of nuclear factor-κβ ligand (sRANKL) in overweight and obese children

被引:0
|
作者
Erazmus, Michal [1 ]
Ruminska, Malgorzata [1 ]
Witkowska-Sedek, Ewelina [1 ]
Kucharska, Anna M. [1 ]
Stelmaszczyk-Emmel, Anna [2 ]
Majcher, Anna [1 ]
Pyrzak, Beata [1 ]
机构
[1] Med Univ Warsaw, Dept Paediat & Endocrinol, Warsaw, Poland
[2] Med Univ Warsaw, Dept Lab Diagnost & Clin Immunol Dev Age, Warsaw, Poland
来源
关键词
sRANKL; OPG; sRANKL ratio; cardiovascular risk factors; obesity; children; LOW SERUM-LEVELS; INSULIN-RESISTANCE; RANK LIGAND; URIC-ACID; VASCULAR CALCIFICATION; METABOLIC SYNDROME; RISK-FACTORS; B LIGAND; OSTEOPROTEGERIN; ATHEROSCLEROSIS;
D O I
10.3389/fendo.2022.963467
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionChildhood obesity contributes to the development of cardiovascular diseases. The molecular pathway - receptor activator of nuclear factor-kappa beta ligand (RANKL), its receptor RANK and osteoprotegerin (OPG) - takes part not only in bone metabolism but is also involved in the atherosclerosis process. RANKL stimulates osteogenic differentiation and calcification of vascular smooth cells. The associations between the OPG-sRANKL system and various cardiovascular risk factors were displayed. We aimed to evaluate the relationships between serum sRANKL (soluble RANKL) levels and the OPG/sRANKL ratio with cardiometabolic risk factors in overweight and obese children. Material and methodsThe study included 70 children with overweight and obesity (mean age 13.0 +/- 2.8) and 35 age-matched normal weight, healthy peers as a control group. In all patients, anthropometric measurements and laboratory tests were performed. Additionally, an oral glucose tolerance test (OGTT) was made only in overweight and obese children. Atherogenic and insulin resistance indices were calculated. ResultsOverweight and obese children had lower sRANKL levels compared to the control group (median 276.95 vs 325.90, p=0.011), and consequently a higher OPG/sRANKL ratio (0.02 vs 0.01, p = 0.013). The studied children in the lowest quartile of sRANKL levels had higher body weight, Body Mass Index, waist circumference and increased glucose and insulin levels 60 minutes after OGTT and higher uric acid values compared to children in the highest quartile. In multivariable linear regression analysis sRANKL negatively correlated only with uric acid (beta = - 0.508, p = 0.041). No association was found for the OPG/sRANKL ratio. ConclusionExcess fat mass seems to alter the OPG/RANKL ratio mainly by reducing serum sRANKL levels. The correlation between sRANKL and uric acid may suggest a contribution of the OPG-sRANKL system in the cardiometabolic process, but that observation should be confirmed in future studies.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Soluble receptor activator of nuclear factor-κB ligand (sRANKL)/osteoprotegerin balance in polymyalgia rheumatica.
    Dolzani, P
    Silvestri, R
    Pulsatelli, L
    Facchini, A
    Boiardi, L
    Salvarani, C
    Meliconi, R
    Codivilla-Putti, I
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S435 - S435
  • [2] Soluble receptor activator of nuclear factor-κB ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases
    Pulsatelli, L
    Dolzani, P
    Silvestri, T
    Caraceni, P
    Facchini, A
    Ravaglia, G
    Salvarani, C
    Meliconi, R
    Mariani, E
    BIOGERONTOLOGY, 2004, 5 (02) : 119 - 127
  • [3] Soluble Receptor Activator of Nuclear Factor-κB Ligand (sRANKL)/Osteoprotegerin Balance in Ageing and Age-Associated Diseases
    Lia Pulsatelli
    Paolo Dolzani
    Tania Silvestri
    Paolo Caraceni
    Andrea Facchini
    Giovanni Ravaglia
    Carlo Salvarani
    Riccardo Melicòni
    Erminia Mariani
    Biogerontology, 2004, 5 : 119 - 127
  • [4] Involvement of soluble receptor activator of nuclear factor-κB ligand (sRANKL) in collagenase-induced murine osteoarthritis and human osteoarthritis
    Petya Dimitrova
    Antoaneta Toncheva
    Valeriya Gyurkovska
    Nina Ivanovska
    Rheumatology International, 2012, 32 : 1317 - 1325
  • [5] Involvement of soluble receptor activator of nuclear factor-κB ligand (sRANKL) in collagenase-induced murine osteoarthritis and human osteoarthritis
    Dimitrova, Petya
    Toncheva, Antoaneta
    Gyurkovska, Valeriya
    Ivanovska, Nina
    RHEUMATOLOGY INTERNATIONAL, 2012, 32 (05) : 1317 - 1325
  • [6] Soluble receptor activator of nuclear factor-κB ligand and risk for cardiovascular disease
    Kiechl, Stefan
    Schett, Georg
    Schwaiger, Judith
    Seppi, Klaus
    Eder, Paula
    Egger, Georg
    Santer, Peter
    Mayr, Agnes
    Xu, Qingbo
    Willeit, Johann
    CIRCULATION, 2007, 116 (04) : 385 - 391
  • [7] The role of circulating osteoprotegerin and receptor activator of nuclear factor ligand (SRANKL) in primary bone mineralization disorders in children
    Chlebna-Sokol, D.
    Lewinski, A.
    Rusinska, A.
    Michalus, I
    Zygmunt, A.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S339 - S339
  • [8] Receptor activator of nuclear factor-κB ligand activates nuclear factor-κB in osteoclast precursors
    Wei, S
    Teitelbaum, SL
    Wang, MWH
    Ross, FP
    ENDOCRINOLOGY, 2001, 142 (03) : 1290 - 1295
  • [9] Antibodies to receptor activator of nuclear factor-κ B ligand (RANKL)
    Terpos, Evangelos
    Christoulas, Dimitrios
    Dimopoulos, Meletios-Athanassios
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2008, 18 (11) : 1265 - 1269
  • [10] Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing
    Colombini, Alessandra
    Lombardi, Giovanni
    Galliera, Emanuela
    Dogliotti, Giada
    Randelli, Pietro
    Meerssemann, Alexander
    Mineo, Giuseppe
    Cabitza, Paolo
    Corsi, Massimiliano Marco
    INTERNATIONAL ORTHOPAEDICS, 2011, 35 (05) : 777 - 782